Last reviewed · How we verify
Pneumococcal Vaccine Polyvalent-Pneumovax 23 — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
Pneumococcal Vaccine Polyvalent-Pneumovax 23 (Pneumococcal Vaccine Polyvalent-Pneumovax 23) — Sanofi.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Pneumococcal Vaccine Polyvalent-Pneumovax 23 TARGET | Pneumococcal Vaccine Polyvalent-Pneumovax 23 | Sanofi | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Pneumococcal Vaccine Polyvalent-Pneumovax 23 CI watch — RSS
- Pneumococcal Vaccine Polyvalent-Pneumovax 23 CI watch — Atom
- Pneumococcal Vaccine Polyvalent-Pneumovax 23 CI watch — JSON
- Pneumococcal Vaccine Polyvalent-Pneumovax 23 alone — RSS
Cite this brief
Drug Landscape (2026). Pneumococcal Vaccine Polyvalent-Pneumovax 23 — Competitive Intelligence Brief. https://druglandscape.com/ci/pneumococcal-vaccine-polyvalent-pneumovax-23. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab